ClinicalTrials.gg
RecruitingNCT07023835UNITE-ALSUpdated Sep 1, 2026

Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

A Phase 2 interventional study of 50 mg Usnoflast and 75 mg Usnoflast in Amyotrophic Lateral Sclerosis (ALS), sponsored by Zydus Therapeutics Inc.. Recruiting at 49 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Zydus Therapeutics Inc. (part of Zydus Lifesciences Limited) · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.

Planned enrollment
36th of 307
240 · median 33
Started
2025
with 26 others
Phase 2
89 of 440
8 open now
Primary completion
2028-03
later than 76 of 128 live
Registered
390th of 440
by date

Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 36th largest by planned enrollment of the 307 interventional ones that give a count, is one of 27 that started in 2025, is one of 89 in phase 2, reaches primary completion later than 76 of the 128 other live ones, and was the 390th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, or all of them as a file.
02

Study summary

Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

Read the detailed description

A phase 2b, randomized, double-blind, placebo-controlled, parallel-group, multicenter 36 weeks study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of Usnoflast administered to adult subjects with Amyotrophic Lateral Sclerosis followed by 16 weeks open label extension study.

This Open Label Extension will be a multicenter, 16-week, single arm study to confirm the long-term safety and efficacy of Usnoflast in subjects with ALS. Eligible subjects of all three arms of the main study will be recruited in the OLE phase and will receive Usnoflast (75 mg) for a total of 16 weeks BID (oral capsule administration).

03

Conditions studied

  • Amyotrophic Lateral Sclerosis (ALS)

Keywords

  • Amyotrophic Lateral Sclerosis,
  • ALS
  • Usnoflast
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Diagnosis of probable or definite Amyotrophic lateral sclerosis, according to the revised version of the El Escorial World Federation of Neurology criteria
  • Time since onset of first symptom of Amyotrophic lateral sclerosis ≤24 months. Date of Amyotrophic lateral sclerosis symptom onset. For the purposes of this study, the date of symptom onset will be defined as the date the subject first had symptoms of their disease, i.e., limb weakness, dysarthria, dysphagia, shortness of breath, or fasciculations, from the screening visit.
  • Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised score of ≥35 at screening.
  • Slow vital capacity: ≥60% of predicted capacity at the screening visit.
  • Be able to swallow capsules.
  • Either not currently receiving riluzole/sodium phenylbutyrate and taurursodiol/tofersen or on a stable dose of riluzole/sodium phenylbutyrate and taurursodiol/tofersen for at least 4 weeks before the screening visit. Subjects receiving riluzole/sodium phenylbutyrate and taurursodiol/tofersen are expected to remain on the same dose throughout the duration of the study.
  • Either not currently receiving edaravone or on edaravone treatment. Subjects receiving edaravone must have completed at least 1 cycle of treatment before the screening visit and are expected to continue with a stable dose of edaravone treatment throughout the duration of the study.
  • Capable of providing and complying with study procedures in the opinion of the investigator

Exclusion Criteria:

  • Presence of unstable psychiatric disease, cognitive impairment, dementia, or substance abuse that would impair the ability of the subject to provide informed consent, in the opinion of the investigator.
  • Serious illness (e.g., pneumonia, septicemia) within 4 weeks of the screening visit; infection requiring hospitalization or treatment with intravenous antibiotics, antivirals, or antifungals within 4 weeks of screening; chronic bacterial infection (such as tuberculosis) deemed unacceptable as per the judgment of the investigator.
  • Active herpes zoster infection within 2 months prior to the screening visit.
  • Any medical condition that promotes suicidal attempt or behavior within 6 months prior to the screening visit and in the opinion of the investigator might interfere with subject's participation in the study or is a risk for a suicide attempt.
  • History of unstable or severe cardiac, pulmonary, oncological, hepatic, or renal disease or active cancer or another medically significant illness other than Amyotrophic lateral sclerosis, precluding safe participation of subject in this study in the opinion of the investigator.
  • Known allergy, sensitivity, or intolerance to product or .
  • Subjects who have taken concomitant medications that are substrates of drug metaboliz-ing enzymes (Cytochrome P450 1A2 and/or Cytochrome P450 2B6) within 7 days or 5 half-lives of the medication (whichever is longer) before the first dose of Investigational product and throughout the study.
  • Use of any , colchicine, or anti-IL-1 inhibitors within 7 days or 5 half-lives of the medication (whichever is longer) prior to the first dose of Investigational product administration.
  • Use of any investigational drug concurrently or within 4 weeks or 5 half-lives (whichever is longer) prior to the first dose of Investigational product administration.
  • Any condition and/or laboratory significant value that would prevent the subject from participating in the study in the opinion of the investigator.
  • Received a within 14 days before the screening visit or planning to receive during the study duration.
  • Subjects who have received stem cell or gene therapy for Amyotrophic lateral sclerosis at any time in the past.
  • Following laboratory test values at screening:

    1. or Aspartate aminotransferase values >3.0 ×
    2. >1.5 × Upper Limit of Normal unless the subject has documented Gilbert's syndrome (isolated bilirubin >1.5 × Upper Limit of Normal is acceptable if bilirubin is fractionated, and direct bilirubin is \<35%)
    3. Estimated (eGFR) \<60 mL/min/1.73 m2
  • For those participating in the optional Cerebrospinal fluid collection, to lumbar puncture including but not limited to lumbar scoliosis, coagulopathy, infection at site of puncture, or use of anticoagulants.
  • Subjects with history of epilepsy within 6 months of screening visit.
  • Surgery within last 3 months or planned major surgery within next 3 months from the date of screening (other than minor cosmetic surgery and minor dental surgery).
  • Use or intended use of any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's Wort, within 4 weeks of screening and up to end of study. Use of such medication will be considered on a case-by-case basis as per the opinion of the investigator and/or independent medical monitor.
  • Receiving an elemental diet or parenteral nutrition.
  • Received blood transfusion within 3 months prior to screening.
  • Subjects with , , , coronary artery disease, or active gastrointestinal condition that might interfere with drug absorption.
  • Inability to be venipunctured or those not able to tolerate venous puncture.
  • Employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as family members of employees of investigator or the investigator.
  • Any condition not mentioned in any of above criteria that, as per the investigator, would hinder participation of the subject in the study. This may include, but not limited to, considerations of safety, compliance, or other factors that could impact the integrity of the study or the well-being of the subject.
  • If female, breastfeeding, known to be pregnant, planning to become pregnant during the study, or of and unwilling to use effective during the study and for at least 1 month after administration of last dose of Investigational product. If male of reproductive capacity, unwilling to use effective contraception during the study and for at least 1 month after administration of last dose of Investigational product.

For Open Label Extension

Inclusion Criteria:

  • Completion in the randomized, double blind Usnoflast study (main study).
  • Subjects who elect to continue treatment after completion of Usnoflast phase 2b study must enrol in the OLE within 28 days of the completion of Week 36 visit of the main study.
  • Provide a new informed consent to enter the OLE phase.

Exclusion Criteria:

  • Discontinued IP prematurely in the double-blind phase of the study for reasons other than tracheostomy or permanent-assisted ventilation.
  • Treatment with or use of any restricted medications.
  • Any ongoing AE that, in the opinion of the site investigator, is clear contraindication to the IP.
  • Unstable cardiac or other life-threatening disease emergent during the randomized, double-blind study
  • Any major medical history or other evidence of severe illness or any other conditions that would make the subject, in the opinion of the investigator, unsuitable for the study.
  • If female, breastfeeding, known to be pregnant, planning to become pregnant during the study, or of child-bearing potential and unwilling to use effective contraception during the study and for at least 1 month after administration of last dose of IP. If male of reproductive capacity, unwilling to use effective contraception during the study and for at least 1 month after administration of last dose of IP.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Active comparator
    50 mg Usnoflast

    50 mg Usnoflast capsules and matching placebo of 25 mg capsule under fasting conditions twice a day orally for 36 weeks

    Drug: 50 mg Usnoflast

  • Active comparator
    75 mg Usnoflast

    25 mg + 50 mg Usnoflast capsules under fasting conditions twice a day orally for 36 weeks

    Drug: 75 mg Usnoflast

  • Placebo comparator
    Placebo

    Matching placebo of 25 mg and 50 mg under fasting conditions twice a day orally for 36 weeks

    Drug: Placebo

Interventions

  • DrugZYIL1Studies of ZYIL1ZYIL1 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    50 mg Usnoflast (50 mg Usnoflast capsules and matching placebo of 25 mg capsule)

    Also known as: Not any

  • DrugZYIL1Studies of ZYIL1ZYIL1 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    75 mg Usnoflast (25 mg + 50 mg Usnoflast capsules)

    Also known as: Not any

  • DrugPlacebo

    Matching placebo of 25 mg and 50 mg

    Also known as: Not any

06

What researchers measure

Primary outcomes

  1. Efficacy of Usnoflast versus placebo assessed using the revised ALSFRS-R total score

    Change in disease progression from baseline through Week 36 as measured by ALSFRS-R total score

    Time frame: From baseline through Week 36

  2. Efficacy of Usnoflast versus placebo assessed using the survival

    Change in disease progression from baseline through Week 36 as measured by survival Survival is defined based on the time of death or permanent-assisted ventilation (PAV). PAV is defined as the use of invasive or noninvasive mechanical ventilation for \>22 hours daily for \>7 consecutive days

    Time frame: From baseline through Week 36

  3. Effect of Usnoflast versus placebo on survival in Open label extension phase

    Time from baseline to the occurrence of death or Permanent-assisted ventilation (\>22 hours daily for \>7 days)

    Time frame: From baseline through Week 16

  4. Number of participants with treatment emergent adverse events in open label extension

    Time from baseline

    Time frame: From baseline through Week 16

  5. Number of participants with Serious adverse events in open label extension

    Time from baseline

    Time frame: From baseline through Week 16

Secondary outcomes

  1. Effect of Usnoflast versus placebo on survival

    Time from baseline to the occurrence of death or Permanent-assisted ventilation (\>22 hours daily for \>7 days)

    Time frame: From baseline through Week 36

  2. Evaluate the effect of Usnoflast versus placebo on Slow vital capacity

    Change in Slow vital capacity from baseline to Week 36

    Time frame: from baseline to Week 36

  3. Evaluate the effect of Usnoflast versus placebo on serum levels of Neurofilament light chain protein

    Change in serum levels of Neurofilament light chain protein from baseline to Week 36

    Time frame: From baseline to Week 36

  4. Evaluate the effect of Usnoflast versus placebo on Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised total score and various functional items/domains of the ALSFRS-R total score

    To determine the rate of disease progression using the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised total score and scores of various functional items/domains of the ALSFRS-R total score from baseline to Week 36

    Time frame: From baseline to Week 36

  5. Evaluate and compare the effect of Usnoflast versus placebo on overall health-related quality of life

    Change in Amyotrophic Lateral Sclerosis assessment questionnaire-40 (ALSAQ-40) score from baseline to Week 36

    Time frame: From baseline to Week 36

  6. Number of participants with treatment emergent adverse events

    Time from baseline

    Time frame: From baseline to Week 36

  7. Number of participants with Serious adverse events

    Time from baseline

    Time frame: From baseline to Week 36

  8. Evaluate Pharmacokinetic of Usnoflast in plasma

    Peak steady state plasma concentration (Cmax,ss)

    Time frame: PK time pts: pre-dose, 2, 4, 6, 8 hours ±30 mins post morning dose at Day 1, Week 16, and Week 36

  9. Evaluate Pharmacokinetic of Usnoflast in plasma

    Time to reach peak plasma concentration at steady state (Tmax,ss)

    Time frame: PK time pts: pre-dose, 2, 4, 6, 8 hours ±30 mins post morning dose at Day 1, Week 16, and Week 36

  10. Evaluate Pharmacokinetic of Usnoflast in plasma

    Accumulation index calculated as a ratio of AUCtau (last dose)/AUCtau (first dose)

    Time frame: PK time pts: pre-dose, 2, 4, 6, 8 hours ±30 mins post morning dose at Day 1, Week 16, and Week 36

  11. Evaluate Pharmacokinetic of Usnoflast in plasma

    Area under Plasma concentration vs. time curve till the last time point: AUC0-t

    Time frame: PK time pts: pre-dose, 2, 4, 6, 8 hours ±30 mins post morning dose at Day 1, Week 16, and Week 36

  12. Evaluate Pharmacokinetic of Usnoflast in plasma

    Area under Plasma concentration vs. time curve extrapolated to the infinity: AUC0-∞

    Time frame: PK time pts: pre-dose, 2, 4, 6, 8 hours ±30 mins post morning dose at Day 1, Week 16, and Week 36

  13. Evaluate Pharmacokinetic of Usnoflast in plasma

    Area under Plasma concentration vs. time curve based on extrapolation: AUCextap

    Time frame: PK time pts: pre-dose, 2, 4, 6, 8 hours ±30 mins post morning dose at Day 1, Week 16, and Week 36

  14. Evaluate Pharmacokinetic of Usnoflast in plasma

    Elimination rate constant (Kel)

    Time frame: PK time pts: pre-dose, 2, 4, 6, 8 hours ±30 mins post morning dose at Day 1, Week 16, and Week 36

  15. Evaluate Pharmacokinetic of Usnoflast in plasma

    Elimination half-life (t1/2)

    Time frame: PK time pts: pre-dose, 2, 4, 6, 8 hours ±30 mins post morning dose at Day 1, Week 16, and Week 36

  16. Evaluate Pharmacokinetic of Usnoflast in Cerebrospinal fluid

    The concentration of Usnoflast in CSF.

    Time frame: PK time pts: pre-dose, 2, 4, 6, 8 hours ±30 mins post morning dose at Day 1, Week 16, and Week 36

  17. Effect of Usnoflast versus placebo on Cerebrospinal fluid levels of Neurofilament light chain protein

    Change in Cerebrospinal fluid levels of Neurofilament light chain protein

    Time frame: From baseline to Week 36

  18. To determine the rate of disease progression in open label extension

    Change in Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised total score and scores of various functional items/domains of the ALSFRS-R total score from baseline to Week 16

    Time frame: From baseline to Week 16

07

Study locations

25 of 49 sites recruiting
  • Zydus US015
    La Jolla, California 92037, United States
    Recruiting
  • Zydus US008
    Orange, California 92868, United States
    Not yet recruiting
  • Zydus US013
    San Francisco, California 94109, United States
    Recruiting
  • Zydus US005
    New Britain, Connecticut 06053, United States
    Recruiting
  • Zydus US012
    Tampa, Florida 80045, United States
    Recruiting
  • Zydus US007
    Atlanta, Georgia 30322, United States
    Recruiting
  • Zydus US010
    Boston, Massachusetts 02114, United States
    Recruiting
  • Zydus US006
    Detroit, Michigan 48202, United States
    Recruiting
  • Zydus US014
    Lincoln, Nebraska 68510, United States
    Recruiting
  • Zydus US003
    Winston-Salem, North Carolina 27157, United States
    Recruiting
  • Zydus US009
    Pittsburgh, Pennsylvania 15212, United States
    Recruiting
  • Zydus US001
    Dallas, Texas 75206, United States
    Recruiting
  • Zydus US002
    Houston, Texas 77030, United States
    Recruiting
  • Zydus US004
    Richmond, Virginia 23298, United States
    Recruiting
  • Zydus US011
    Seattle, Washington 98122, United States
    Recruiting
  • Zydus 200
    Caulfield South, Australia, Australia
    Recruiting
  • Zydus 201
    Sydney, New South Wales, Australia
    Recruiting
  • Zydus 202
    Southport, Australia
    Not yet recruiting
  • Zydus 110
    Leuven, Belgium, Belgium
    Not yet recruiting
  • Zydus 101
    Toronto, Ontario ON M4N 3M5, Canada
    Not yet recruiting
  • Zydus 100
    Québec, Quebec QC H4A 3T2, Canada
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Zydus 124
    Clermont-Ferrand, France, France
    Not yet recruiting
  • Zydus 122
    Limoges, France, France
    Not yet recruiting
  • Zydus 123
    Montpellier, France, France
    Recruiting
  • Zydus 125
    Nice, France, France
    Recruiting
  • Zydus 120
    Paris, France, France
    Recruiting
  • Zydus 121
    Tours, France, France
    Recruiting
  • Zydus 130
    Dresden, Germany, Germany
    Not yet recruiting
  • Zydus 133
    Hanover, Germany, Germany
    Not yet recruiting
  • Zydus 134
    Jena, Germany, Germany
    Not yet recruiting
  • Zydus 131
    Lübeck, Germany, Germany
    Not yet recruiting
  • Zydus 132
    Rostock, Germany, Germany
    Not yet recruiting
  • Zydus 135
    Ulm, Germany, Germany
    Not yet recruiting
  • Zydus 140
    Dublin, Ireland, Ireland
    Not yet recruiting
  • Zydus 154
    Genova, Italy, Italy
    Not yet recruiting
  • Zydus 153
    Milan, Italy, Italy
    Not yet recruiting
  • Zydus 151
    Modena, Italy, Italy
    Not yet recruiting
  • Zydus 152
    Naples, Italy, Italy
    Recruiting
  • Zydus 150
    Brescia, Italy
    Recruiting
  • Zydus 160
    Utrecht, Netherlands, Netherlands
    Recruiting
  • Zydus 170
    Krakow, Poland, Poland
    Not yet recruiting
  • Zydus 171
    Warsaw, Poland, Poland
    Not yet recruiting
  • Zydus 180
    Alicante, Spain, Spain
    Not yet recruiting
  • Zydus 181
    Barcelona, Spain, Spain
    Not yet recruiting
  • Zydus 182
    Málaga, Spain, Spain
    Not yet recruiting
  • Zydus 183
    Valencia, Spain, Spain
    Recruiting
  • Zydus 191
    Malmö, Sweden, Sweden
    Recruiting
  • Zydus 190
    Stockholm, Sweden, Sweden
    Not yet recruiting
  • Zydus 192
    Umeå, Sweden, Sweden
    Not yet recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Mar 2028, 30 months after the start.

Of 36 industry-sponsored phase 2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 35. This study's planned 30 months is above that.

Counting every sponsor, half of 73 studies reached it within 24 months; a quarter within 16 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2025
First posted
Jun 17, 2025
StartActual
Sep 17, 2025
Primary completionEst.
Mar 2028
CompletionEst.
Oct 2028
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07023835
Responsible party
Sponsor
First posted
Jun 17, 2025
Start date
Sep 17, 2025
Primary completion
Mar 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Sep 1, 2026

Study contacts

Farheen Shaikh
Contact
fshaikh@zydustherapeutics.com
6094534751
Deven V Parmar
study director · Zydus Therapeutics Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion